Compositions comprising TNF-specific antibodies for oral delivery and methods of use thereof to treat inflammatory bowel disease
In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract.
1. A composition for oral delivery to a human patient comprising ruminant-derived anti-TNF antibodies, wherein upon oral administration of the antibodies to the digestive tract of the patient, the antibodies are therapeutically effective to treat inflammatory bowel disease in the patient, and wherein the antibodies are present in the composition at a dosage of about 1 mg per day to about 1 gram per day.
2. The composition of claim 1 , formulated as a solid dosage form for oral administration.
3. The composition of claim 2 , wherein the solid dosage form is selected from capsules, tablets, pills powders and granules.
4. The composition of claim 2 , wherein the solid dosage comprises an enteric coating.
5. The composition of claim 1 , wherein the anti-TNF antibodies are derived from the serum of a ruminant that has been immunized with TNF or any antigenic fragment thereof.
6. The composition of claim 5 , wherein the antibodies are IgG antibodies.
7. The composition of claim 5 , wherein the antibodies are IgG1 antibodies.
8. The composition of claim 1 , wherein the antibodies are IgG antibodies.
9. The composition of claim 1 , wherein the antibodies are IgG1 antibodies.
10. The composition of claim 1 , wherein the ruminant is a bovine.
11. The composition of claim 5 , wherein the ruminant is a bovine.
12. A method of treating inflammatory bowel disease in a human patient comprising orally administering to a patient in need thereof an effective amount of a composition of claim 1 .
13. A method of treating inflammatory bowel disease in a human patient comprising orally administering to the human patient in need thereof an effective amount of a composition of claim 10 .
14. A method of treating inflammatory bowel disease in a human patient comprising orally administering to the human patient in need thereof an effective amount of a composition of claim 5 .